Safety releated events for Cohorts 1A, 1B and 2B.

Safety Population

A DLT is an adverse event or abnormal lab value not related to disease progression, illness, or other medications. The DLT evaluation period is 5 weeks (35 days) for both BMS-986288 monotherapy and combination dose escalation. Toxicities beyond this period will inform final dose decisions. Participants who discontinue due to a DLT or complete the 5-week period after receiving at least 2 doses are considered DLT-evaluable. Those who withdraw early or receive fewer than 2 doses for non-DLT reasons are not evaluable and may be replaced. Participants with dose delays for non-DLT reasons remain evaluable if they receive at least 2 doses within 8 weeks.

As Per Protocol, DLT Evaluable Participants in 1A, 1B and 2B.

The percentage of all treated participants whose BOR is either CR or PR by BICR per RECIST v1.1.

Safety Population

The percentage of all treated participants whose BOR is either CR or PR by Investigator per RECIST v1.1.

All Treated Participants in Cohort 1A, 1B and 2B

Duration of response is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the 1st objectively documented tumor progression as determined by Investigator (per RECIST 1.1), or death due to any cause, whichever occurs first.

All Treated Participants in Cohort 1A, 1B and 2B who achievied CR or PR

Time to response (TTR) assessed by investigator is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria.

All Treated Participants in Cohort 1A, 1B and 2B who achievied CR or PR

PFS is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by investigator or death due to any cause, whichever is earlier.

All Treated Participants in Cohort 1A, 1B and 2B

Duration of response is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the 1st objectively documented tumor progression as determined by BICR (per RECIST 1.1), or death due to any cause, whichever occurs first.

All Treated Participants in Cohort 2C who achievied CR or PR

PFS is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier.

Safety Population

OS is defined as the time from randomization to the time of death due to any cause.

Safety Population

The percentage of all treated participants whose BOR is either CR or PR by Investigator per RECIST v1.1.

Safety Population

Duration of response is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the 1st objectively documented tumor progression as determined by Investigator (per RECIST 1.1), or death due to any cause, whichever occurs first.

All Treated Participants in Cohort 2C who achievied CR or PR

PFS is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by investigator or death due to any cause, whichever is earlier.

Safety Population

Safety Related Events in Cohort 2C

Safety Population

A DLT is an adverse event or abnormal lab value not related to disease progression, illness, or other medications. The DLT evaluation period is 5 weeks (35 days) for both BMS-986288 monotherapy and combination dose escalation. Toxicities beyond this period will inform final dose decisions. Participants who discontinue due to a DLT or complete the 5-week period after receiving at least 2 doses are considered DLT-evaluable. Those who withdraw early or receive fewer than 2 doses for non-DLT reasons are not evaluable and may be replaced. Participants with dose delays for non-DLT reasons remain evaluable if they receive at least 2 doses within 8 weeks.

As Per Protocol, DLT Evaluable Participants in 2C.

Cmax is defined as maximum plasma concentration of the drug.

PK Evaluable Population

Tmax is defined is the time to maximum plasma concentration

PK Evaluable Population

Area under the plasma concentration time-curve. AUC from time 0 to the last time of quantifiable concentration.

PK Evaluable Population

Area under the plasma concentration time-curve. AUC over the dosing interval.

PK Evaluable Population

Ctau is defined as the concentration of study drug at the end of the dosing interval

PK Evaluable Population